Published: May 20th 2025 | Updated: June 4th 2025
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
Published: May 19th 2025 | Updated: May 20th 2025
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: June 19th 2025 | Updated: June 23rd 2025
Patient Factors Determine Treatment Selection for PD-L1 Negative NSCLC
Published: March 8th 2024 | Updated: June 23rd 2025
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing